Key Takeaway
- A proper TRT assessment requires nine blood markers: total testosterone, free testosterone, SHBG, LH, FSH, oestradiol, PSA, full blood count, and a metabolic panel. Most GP panels test only one or two of these.
- Total testosterone on its own misses up to 30% of genuinely deficient men, because elevated SHBG can suppress free testosterone even when the total reading looks normal.
- LH and FSH separate primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary signalling failure), which changes the treatment pathway and whether further investigation is needed.
- Haematocrit is the single most important on-treatment safety marker, because testosterone increases red blood cell production and unchecked elevation raises the risk of clots and stroke.
- TRT Australia requires the full nine-marker pre-treatment panel for every patient and repeats it at 8 weeks and then every 4 months under independent doctor review.
Blood Markers Separate Accurate Diagnosis From Guesswork
A complete TRT blood panel includes nine markers: total testosterone, free testosterone, SHBG, LH, FSH, oestradiol, PSA, a full blood count (with haematocrit), and a metabolic panel. Total testosterone alone tells you whether overall production sits inside the reference range, but free testosterone, SHBG, LH, and FSH are what reveal whether you are genuinely deficient and why. Many Australian men arrive at TRT after a GP test came back “within range” despite years of fatigue, low libido, and flat mood, and a partial panel is the most common reason that conversation goes nowhere.
This guide walks through what each marker measures, how collection timing affects accuracy, and what ongoing monitoring looks like once treatment begins.
TRT Australia: Reclaim Your Strength & EnergyAustralia’s #1 TRT Telehealth Clinic | Doctor-Managed Treatment
Designed for Men’s Hormone Health:
The TRT Australia Difference:
Trust & Medical Excellence: We’re a national telehealth provider focused exclusively on testosterone replacement therapy. Education-first approach with 24/7 medical supervision and monitoring. |
What Does a Comprehensive TRT Pre-Treatment Panel Measure?
Each marker in a comprehensive TRT panel answers a question the others cannot; removing any single test leaves a diagnostic gap that can lead to misdiagnosis, inappropriate prescribing, or missed safety concerns.
Total Testosterone: The Starting Point, Not the Endpoint
Total testosterone measures every testosterone molecule in your bloodstream, including the 60 to 70% bound to SHBG (biologically inactive), the 25 to 35% loosely bound to albumin (partially available), and the 1 to 3% circulating as free testosterone (fully active). Australian laboratory reference ranges typically span 8 to 30 nmol/L.
This marker establishes whether overall production is within, below, or above normal ranges. It is essential but insufficient on its own. A reading of 14 nmol/L could represent adequate hormonal function or genuine clinical deficiency depending entirely on how much of that total is free versus bound. That distinction requires the next two markers.
Free Testosterone: What Your Cells Actually Receive
Free testosterone is the unbound fraction available for biological activity. It is the fraction that binds to androgen receptors in muscle, brain, bone, and reproductive tissue, and the portion that determines whether a man experiences the effects of adequate testosterone or the symptoms of deficiency.
Free testosterone is calculated from total testosterone, SHBG, and albumin using validated formulas (the Vermeulen equation is the most widely used). Some laboratories measure it directly via equilibrium dialysis, though this method is less commonly available and more expensive.
SHBG: The Binding Protein That Explains the Gap
Sex hormone-binding globulin is a protein produced primarily by the liver that binds testosterone with high affinity, rendering it biologically inactive. SHBG levels are influenced by age (increases), obesity (decreases), liver disease (increases), thyroid dysfunction (increases with hyperthyroidism), insulin resistance (decreases), and certain medications.
SHBG does not affect testosterone production. It affects testosterone availability. Two men with identical total testosterone can have very different free testosterone levels depending on how much is bound by SHBG before reaching target tissues.
LH and FSH: Tracing Deficiency to Its Source
Luteinising hormone (LH) and follicle-stimulating hormone (FSH) are pituitary hormones that regulate testicular function. LH stimulates Leydig cells to produce testosterone. FSH stimulates Sertoli cells involved in sperm production. Their levels reveal whether low testosterone originates from testicular failure or pituitary signalling failure, a distinction with direct implications for treatment and further investigation.
- Primary hypogonadism (testicular failure): The testes are not responding to pituitary signals. LH and FSH are elevated because the pituitary is signalling harder to compensate for inadequate testicular output.
- Secondary hypogonadism (pituitary or hypothalamic failure): The signalling system itself is underperforming. LH and FSH are low or inappropriately normal despite low testosterone because the pituitary is not generating adequate stimulation.
Oestradiol: The Conversion Marker
Testosterone converts to oestradiol (a form of oestrogen) through the enzyme aromatase, which is concentrated in fat tissue. This conversion is a normal physiological process, but excessive oestradiol produces its own symptom set: fluid retention, mood disturbance, breast tissue tenderness or growth (gynaecomastia), and paradoxically reduced libido despite adequate testosterone.
Pre-treatment relevance: Baseline oestradiol establishes your starting conversion rate. Men with higher body fat percentages or genetic predisposition to aromatase activity tend to convert more testosterone to oestradiol.
On-treatment relevance: As testosterone increases with TRT, more substrate is available for aromatase conversion. Oestradiol monitoring at each follow-up blood draw ensures this conversion stays within acceptable ranges.
PSA: Prostate Safety Baseline
Prostate-specific antigen is a protein produced by the prostate gland. Elevated PSA can indicate prostate inflammation, benign enlargement, or prostate cancer.
A normal baseline PSA provides the reference point against which all future measurements are compared. If PSA rises significantly during treatment, that change can be evaluated in context rather than in isolation. A man whose pre-treatment PSA was 0.8 ng/mL who rises to 2.0 ng/mL during TRT warrants investigation. Without the baseline, that 2.0 reading has no comparative context.
Full Blood Count: The Haematocrit Imperative
Full blood count measures multiple blood cell parameters, but for TRT assessment and monitoring, haematocrit is the critical value. Haematocrit represents the percentage of blood volume occupied by red blood cells. Normal range for men is approximately 40 to 52%.
Testosterone stimulates erythropoiesis (red blood cell production). This is a normal physiological effect, but unchecked elevation of haematocrit above 52 to 54% increases blood viscosity, raising the risk of thrombotic events (blood clots), stroke, and cardiovascular complications. Haematocrit is the single most important safety marker tracked throughout testosterone therapy.
Metabolic Panel: The Health Context
A metabolic panel including fasting glucose, HbA1c, liver function tests (ALT, AST, GGT), and a lipid profile (total cholesterol, LDL, HDL, triglycerides) provides the broader health context within which TRT operates.
Why it matters: Testosterone deficiency is associated with metabolic syndrome, insulin resistance, and unfavourable lipid profiles. Understanding your metabolic baseline before treatment allows your doctor to track whether TRT produces the expected metabolic improvements (reduced total cholesterol, lower triglycerides, improved insulin sensitivity) and to identify pre-existing conditions that require monitoring or parallel treatment.
What Gets Tracked Once You Start TRT?
Post-treatment blood work serves dual purposes: confirming testosterone has reached therapeutic levels and ensuring safety markers remain within acceptable ranges as the body adapts to restored hormone levels.
The 8-Week Panel: First Assessment of Response
Eight weeks after initiating treatment, a comprehensive blood draw assesses how your body is responding. This panel includes:
Testosterone (total and free): Has the prescribed dose brought levels into the therapeutic range? Are levels too low (requiring dose increase), appropriate (continue current protocol), or too high (requiring reduction)?
Oestradiol: Has increased testosterone substrate produced excessive aromatase conversion? If oestradiol is significantly elevated, protocol adjustments (typically increased injection frequency to flatten testosterone peaks, which reduces aromatase stimulation) may be needed.
Haematocrit: Has red blood cell production increased beyond acceptable limits? This is the most time-sensitive safety check, as haematocrit can rise meaningfully within the first two months of treatment.
PSA: Has prostate-specific antigen changed from baseline? Significant early increases warrant investigation.
Liver function: Are hepatic markers stable?
The 4-Month Cycle: Sustained Oversight
Following the initial 8-week assessment, blood work repeats every 4 months for the duration of treatment. Each cycle includes the same comprehensive panel, allowing your doctor to track:
Testosterone stability: Are levels consistently within therapeutic range, or do seasonal, lifestyle, or health changes require periodic adjustment?
Haematocrit trends: Even if haematocrit was acceptable at 8 weeks, it can continue rising over subsequent months. Sustained monitoring catches gradual elevation before it reaches dangerous thresholds.
Oestradiol management: Conversion rates can shift as body composition changes (common during TRT as fat mass decreases and lean mass increases, which alters aromatase activity). Regular checks ensure this balance remains stable.
PSA trajectory: A single elevated PSA reading can reflect infection, recent ejaculation, vigorous exercise, or benign fluctuation. Tracking the trajectory across multiple readings distinguishes transient variation from clinically significant trends.
Metabolic improvements: Lipid profiles, fasting glucose, and liver function tracked over time demonstrate whether TRT is producing the metabolic benefits research associates with testosterone restoration.
When Additional Testing Is Warranted
Standard monitoring covers the majority of clinical scenarios. Occasionally, additional tests are ordered based on specific findings:
Prolactin: If LH and FSH were unexpectedly low on pre-treatment testing, prolactin measurement helps rule out prolactinoma (a benign pituitary tumour that suppresses gonadotropin secretion).
Thyroid function (TSH, free T3, free T4): If fatigue, mood, or cognitive symptoms persist despite adequate testosterone restoration, thyroid assessment investigates a common overlapping condition.
Iron studies: If haematocrit elevates disproportionately to testosterone dose, iron studies help determine whether pre-existing iron excess is amplifying the erythropoietic response.
DHEA-S and cortisol: If adrenal insufficiency or dysregulation is suspected based on symptom presentation, these markers evaluate the adrenal component of hormonal health.
How TRT Australia Handles Blood Work for Australian Men
A single total testosterone reading from a routine GP visit can confirm severe deficiency, but it cannot rule it out, identify the cause, or establish whether treatment is safe to begin. The nine-marker panel exists because every one of those questions matters before a prescription is written.
TRT Australia requires the full pre-treatment panel for every man entering treatment, with results reviewed by independent doctors against symptoms before any decision is made. Monitoring then repeats at 8 weeks and every 4 months, so dose, oestradiol, and haematocrit are tracked against your own baseline rather than guessed at.
Start Your Free Consultation Today!
Frequently Asked Questions (FAQs)
Can my GP order the full panel needed for TRT assessment?
Most GPs can order the individual tests, but many don’t include the complete set required for accurate assessment. Free testosterone, SHBG, LH, and FSH are frequently omitted from standard GP panels. If you request specific markers, your GP may order them, though some tests may not be routinely available through all pathology providers. TRT Australia’s panels are designed to capture every clinically relevant marker from the outset.
How often is blood work needed during TRT?
TRT Australia schedules blood work at 8 weeks after treatment initiation (first response assessment), then every 4 months for the duration of treatment. Each draw includes the full panel: testosterone, free testosterone, oestradiol, haematocrit, PSA, and metabolic markers.
What happens if my haematocrit gets too high during treatment?
Elevated haematocrit is the most common safety concern during TRT. If levels rise above 52%, your doctor will typically adjust your protocol: reducing dose, increasing injection frequency, or recommending therapeutic blood donation. Treatment is paused only if haematocrit exceeds 54% and doesn’t respond to protocol modifications.
My GP tested my testosterone and said it’s normal. Should I get retested?
If only total testosterone was measured, or if the draw occurred after midday, comprehensive retesting under controlled conditions is warranted, especially if symptoms persist. Total testosterone within reference range can coexist with genuinely deficient free testosterone when SHBG is elevated. TRT Australia‘s panels include both markers measured during morning hours, frequently revealing clinical pictures that partial testing missed.
*Note: This information is educational only and not medical advice. TRT requires a doctor’s prescription and medical supervision. Pricing estimates are subject to change; please verify current costs with providers like TRT Australia before making treatment decisions.
0 Comments